For the study, seven osteoporotic postmenopausal patients aged 65-70 received the microchip-based implant. Researchers found the drug and device combination was biocompatible, and patients reported no adverse side effects. The company plans to file for regulatory approval for its first microchip device in 2014.
Related Articles on Medical Devices:
Negotiations Over Medical Device Fees Continue in Congressional Hearing
GHX to Create Industry’s First Implantable Devices Supply Chain Solution for Physician Preference Items
Study: CMS Has Incorporated Evidence-Based Medicine Into Medical Technology Decisions
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.